Biology and treatment of primary central nervous system lymphoma

por Algazi, Alain P., Kadoch, Cigall, Rubenstein, James L.
Publicado no Neurotherapeutics (2009)

Treatment of cutaneous melanoma: current approaches and future prospects

por Algazi, Alain P, Soon, Christopher W, Daud, Adil I
Publicado em 2010

New Horizons in Melanoma Treatment: Targeting Molecular Pathways

por Soon, Christopher W. M., Algazi, Alain P., Cha, Edward N., Daud, Adil I.
Publicado em 2010

Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade

por Tsai, Katy K., Pampaloni, Miguel H., Hope, Charity, Algazi, Alain P., Ljung, Britt-Marie, Pincus, Laura, Daud, Adil I.
Publicado no J Immunother Cancer (2016)

Dual MAPK / PI3K pathway inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS mutant and wild type melanoma

por Algazi, Alain P., Esteve-Puig, Rosaura, Nosrati, Adi, Hinds, Brian, Hobbs-Muthukumar, Adele, Nandoskar, Prachi, Ortiz-Urda, Susana, Chapman, Paul B., Daud, Adil
Publicado no Pigment Cell Melanoma Res (2017)

Mortality risk after clinical management of recurrent and metastatic adenoid cystic carcinoma

por Xu, Melody J., Wu, Tara J., van Zante, Annemieke, El-Sayed, Ivan H., Algazi, Alain P., Ryan, William R., Ha, Patrick K., Yom, Sue S.
Publicado no J Otolaryngol Head Neck Surg (2018)

Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy

por Nosrati, Adi, Tsai, Katy K, Goldinger, Simone M, Tumeh, Paul, Grimes, Barbara, Loo, Kimberly, Algazi, Alain P, Nguyen-Kim, Thi Dan Linh, Levesque, Mitchell, Dummer, Reinhard, Hamid, Omid, Daud, Adil
Publicado no Br J Cancer (2017)

Intratumoral plasmid IL-12 electroporation therapy in advanced melanoma patients induces systemic and intratumoral T cell responses: T cell responses induced by plasmid IL-12 elect...

por Greaney, Samantha K., Algazi, Alain P., Tsai, Katy K., Takamura, Kathryn T., Chen, Lawrence, Twitty, Christopher G., Zhang, Li, Paciorek, Alan, Pierce, Robert H., Le, Mai H., Daud, Adil I., Fong, Lawrence
Publicado no Cancer Immunol Res (2019)

Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma

por Levine, Lauren S., Mahuron, Kelly M., Tsai, Katy K., Wu, Clinton, Mattis, Daiva M., Pauli, Mariela L., Oglesby, Arielle, Lee, James C., Spitzer, Matthew H., Krummel, Matthew F., Algazi, Alain P., Rosenblum, Michael D., Alvarado, Michael, Daud, Adil I.
Publicado no Ann Surg Oncol (2020)

Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy

por Loo, Kimberly, Tsai, Katy K., Mahuron, Kelly, Liu, Jacqueline, Pauli, Mariela L., Sandoval, Priscila M., Nosrati, Adi, Lee, James, Chen, Lawrence, Hwang, Jimmy, Levine, Lauren S., Krummel, Matthew F., Algazi, Alain P., Alvarado, Michael D, Rosenblum, Michael D., Daud, Adil I.
Publicado no JCI Insight (2017)

Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies

por Algazi, Alain P., Tsai, Katy K., Shoushtari, Alexander N., Munhoz, Rodrigo R., Eroglu, Zeynep, Piulats, Josep M, Ott, Patrick A., Johnson, Douglas B., Hwang, Jimmy, Daud, Adil I., Sosman, Jeffrey, Carvajal, Richard D., Chmielowski, Bartosz, Postow, Michael A., Weber, Jeffrey S., Sullivan, Ryan J.
Publicado no Cancer (2016)

Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study

por Cohen, Roger B., Delord, Jean-Pierre, Doi, Toshihiko, Piha-Paul, Sarina A., Liu, Stephen V., Gilbert, Jill, Algazi, Alain P., Damian, Silvia, Hong, Ruey-Long, Le Tourneau, Christophe, Day, Daphne, Varga, Andrea, Elez, Elena, Wallmark, John, Saraf, Sanatan, Thanigaimani, Pradeep, Cheng, Jonathan, Keam, Bhumsuk
Publicado no Am J Clin Oncol (2018)

Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma

por Daud, Adil I., Loo, Kimberly, Pauli, Mariela L., Sanchez-Rodriguez, Robert, Sandoval, Priscila Munoz, Taravati, Keyon, Tsai, Katy, Nosrati, Adi, Nardo, Lorenzo, Alvarado, Michael D., Algazi, Alain P., Pampaloni, Miguel H., Lobach, Iryna V., Hwang, Jimmy, Pierce, Robert H., Gratz, Iris K., Krummel, Matthew F., Rosenblum, Michael D.
Publicado no J Clin Invest (2016)

Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF mutated melanoma: a randomized phase 2 trial

por Algazi, Alain P., Othus, Megan, Daud, Adil I., Lo, Roger S., Mehnert, Janice M., Truong, Thach-Giao, Conry, Robert, Kendra, Kari, Doolittle, Gary C., Clark, Joseph I., Messino, Michael J., Moore, Dennis F., Lao, Christopher, Faller, Bryan A., Govindarajan, Rangaswamy, Harker-Murray, Amy, Dreisbach, Luke, Moon, James, Grossmann, Kenneth F., Ribas, Antoni
Publicado no Nat Med (2020)

Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12

por Garris, Christopher S., Arlauckas, Sean P., Kohler, Rainer H., Trefny, Marcel P., Garren, Seth, Piot, Cécile, Engblom, Camilla, Pfirschke, Christina, Siwicki, Marie, Gungabeesoon, Jeremy, Freeman, Gordon J., Warren, Sarah E., Ong, SuFey, Browning, Erica, Twitty, Christopher G., Pierce, Robert H., Le, Mai H., Algazi, Alain P., Daud, Adil I., Pai, Sara I., Zippelius, Alfred, Weissleder, Ralph, Pittet, Mikael J.
Publicado no Immunity (2018)

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC

por Tumeh, Paul C., Hellmann, Matthew D., Hamid, Omid, Tsai, Katy K., Loo, Kimberly L., Gubens, Matthew A., Rosenblum, Michael, Harview, Christina L., Taube, Janis M., Handley, Nathan, Khurana, Neharika, Nosrati, Adi, Krummel, Matthew F., Tucker, Andrew, Sosa, Eduardo V., Sanchez, Phillip J., Banayan, Nooriel, Osorio, Juan C., Nguyen-Kim, Dan L., Chang, Jeremy, Shintaku, I. Peter, Boasberg, Peter D., Taylor, Emma J., Munster, Pamela N., Algazi, Alain P., Chmielowski, Bartosz, Dummer, Reinhard, Grogan, Tristan R., Elashoff, David, Hwang, Jimmy, Goldinger, Simone M., Garon, Edward B., Pierce, Robert H., Daud, Adil
Publicado no Cancer Immunol Res (2017)